

CAVAZZA PAOLO  
Form 4  
December 01, 2017

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Essetifin SPA

2. Issuer Name and Ticker or Trading Symbol  
SOLIGENIX, INC. [SNGX]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)

\_\_\_\_ Director \_\_\_\_\_ 10% Owner  
\_\_\_\_ Officer (give title below)  Other (specify below)

VIA SUDAFRICA, 20

11/29/2017

Former 10% Owner

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)

ROME, L6 00144

\_\_\_\_ Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/29/2017		S	(A) or (D) V Amount Price 271,140 (1) D \$ 2.12	0 (2) (3)	I (3) (6)	Indirect (3)
Common Stock	11/29/2017		P	271,140 (1) A \$ 2.12	271,140 (2) (3)	D (3) (6)	
Common Stock	11/29/2017		S	5,954 (1) D \$ 2.12	0 (4)	I (4) (6)	Indirect (4)
Common Stock	11/29/2017		P	5,954 (1) A \$ 2.12	277,094 (4)	D (4) (6)	
Common Stock	11/29/2017		S	16,416 (1) D \$ 2.12	0 (5)	I (5) (6)	Indirect (5)

Edgar Filing: CAVAZZA PAOLO - Form 4

Common Stock 11/29/2017 P 16,416 (1) A \$ 2.12 293,510 (5) D (5) (6)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned (Instr. 5)
--	--	--------------------------------------	--	--------------------------------	---	--	---	--	--

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Essetifin SPA VIA SUDAFRICA, 20 ROME, L6 00144				Former 10% Owner
CAVAZZA PAOLO VIA TESSERETE, 10 LUGANO, V8 00000				Former 10% Owner
Leadiant Biosciences, Inc. 9841 WASHINGTONIAN BLVD., SUITE 500 GAITHERSBURG, MD 20878				Former 10% Owner
Cavazza Enrico VIA SUDAFRICA, 20 ROME, L6 00144				Former 10% Owner
Cavazza Francesca VIA SUDAFRICA, 20 ROME, L6 00144				Former 10% Owner

Cavazza Silvia  
VIA SUDAFRICA, 20  
ROME, L6 00144

Former 10% Owner

Cavazza Preta Martina  
VIA SUDAFRICA, 20  
ROME, L6 00144

Former 10% Owner

## Signatures

Essetifin S.p.A. By: /s/ Marino Zigrossi	11/30/2017
**Signature of Reporting Person	Date
/s/ Fabio Poma for Paolo Cavazza by power of attorney	11/30/2017
**Signature of Reporting Person	Date
Leadiant Biosciences, Inc. By: /s/ Marino Zigrossi	11/30/2017
**Signature of Reporting Person	Date
/s/ Marino Zigrossi for Enrico Cavazza by power of attorney	11/30/2017
**Signature of Reporting Person	Date
/s/ Marino Zigrossi for Francesca Cavazza by power of attorney	11/30/2017
**Signature of Reporting Person	Date
/s/ Marino Zigrossi for Silvia Cavazza by power of attorney	11/30/2017
**Signature of Reporting Person	Date
/s/ Marino Zigrossi for Martina Cavazza Preta by power of attorney	11/30/2017
**Signature of Reporting Person	Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Effective October 7, 2016, the issuer completed a reverse stock split of its issued and outstanding shares of common stock at a ratio of
- (1) 1-for-10, whereby every 10 shares of its common stock were exchanged for one share of its common stock (the "Reverse Stock Split"). These shares have been adjusted to reflect the Reverse Stock Split.
- This Form 4 reflects the transfer of shares of common stock by each of (i) Leadiant Biosciences, Inc., formerly Sigma Tau Pharmaceuticals Inc., a Nevada corporation ("LBI"); (ii) Paolo Cavazza; and (iii) Sinaf S.A., a Luxembourg corporation ("Sinaf"), to
- (2) Essetifin S.p.A., formerly Sigma Tau Finanziaria S.p.A., an Italian corporation ("Essetifin"). Each transaction is reported as a disposition by the respective seller and an acquisition of the same amount of shares by Essetifin. After giving effect to these transactions, Essetifin beneficially owns an aggregate of 293,510 shares of common stock of the issuer.
- Sold by LBI and purchased by Essetifin pursuant to a purchase agreement by and between Essetifin and LBI. Each of Essetifin and Paolo Cavazza previously reported indirect ownership of such shares due to their respective ownership interests in LBI. Paolo Cavazza
- (3) continues to have an indirect interest in such shares through his ownership interest in Essetifin. After the purchase of these shares by Essetifin, LBI no longer directly holds common stock of the issuer. LBI directly owns warrants to purchase shares of the issuer's common stock.
- Sold by Paolo Cavazza and purchased by Essetifin pursuant to a purchase agreement by and between Essetifin and Paolo Cavazza. Paolo
- (4) Cavazza previously reported direct ownership of such shares and continues to have an indirect interest through his ownership interest in Essetifin.
- (5) Sold by Sinaf and purchased by Essetifin S.p.A., an Italian corporation ("Essetifin"), pursuant to a purchase agreement by and between Essetifin and Sinaf. Paolo Cavazza previously reported indirect ownership of such shares due to his ownership interests in Sinaf, which is a directly wholly-owned subsidiary of Aptafin S.p.A., which is owned indirectly by Paolo Cavazza and members of his family. Paolo

## Edgar Filing: CAVAZZA PAOLO - Form 4

Cavazza continues to have an indirect interest in such shares through his ownership interest in Essetifin.

- (6) Dispositive power over the shares of common stock owned by Essetifin is shared by Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza. Each of Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza disclaims beneficial ownership of all shares of common stock held by Essetifin except to the extent of any pecuniary interest therein.

### **Remarks:**

Exhibit List: Exhibit 24.1 - Power of Attorney; Exhibit 99.1 - Joint Filers' Signatures

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.